Interní Med. 2012; 14(1): 18-20

Autonomous neuropathy and affliction of the myocardium

MUDr.Alena Adamíková, Ph.D., MUDr.Jiří Bakala
Diabetologické centrum, Interní klinika IPVZ, Krajská nemocnice T. Bati, a.s., Zlín
Oddělení nukleární medicíny, Krajská nemocnice T. Bati, a.s., Zlín

Cardiovascular autonomous neuropathy includes abnormalities in the control of cardiac frequency as well as in central and peripheral

vascular dynamics. It afflicts ca 17 % of type 1 diabetic patients and 22 % of type 2 diabetic patients, depending on the method used for

the examination. Diabetes mellitus leads to functional and structural changes of the myocardium, even independently of the presence

of ischemic disease and hypertension. The finding of systolic and diastolic dysfunctions of the left ventricle, myocardial dilatations and

hypertrophy without the presence of macroangiopathy is designated as diabetic cardiomyopathy. Among the causes are to be found

metabolic changes, myocardial fibrosis, microangiopathy as well as cardiovascular autonomous neuropathy, which lead to sympathetic

denervation and alteration of myocardial perfusion. The diagnosis of diabetic cardiomyopathy significantly affects the prognosis of

a diabetic patient. Echocardiography and nuclear medicine methods are used in the diagnostics.

Keywords: diabetes mellitus, cardiovascular autonomous neuropathy, diabetic cardiomyopathy, myocardial scintigraphy

Published: January 30, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adamíková A, Bakala J. Autonomous neuropathy and affliction of the myocardium. Interní Med. 2012;14(1):18-20.
Download citation

References

  1. Ziegler D, Zentai CP, Perz S, et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population The MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31: 556-561. Go to original source... Go to PubMed...
  2. Vinik AI, Maser RE, Mitchell BD. Diabetic autonomic neuropathy. Diabetes Care 2003; 26(5): 1553-1579. Go to original source... Go to PubMed...
  3. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785. Go to original source... Go to PubMed...
  4. Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of cardiac myocytes to current diagnosis and management strategies. Vascular Health and Risk Management 2010; 6: 883-903. Go to original source... Go to PubMed...
  5. Lacigova S, Meinlova J, Gruberova J. The heart of patient with type 1 diabetes. Vnitř Lék 2010; 56(5): 418-426. Go to PubMed...
  6. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995; 26: 135-136.
  7. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducibile measure of cardiac function: a study in normal and dilated cardiomyopathy. J Cardiol 1995; 26: 357-366.
  8. Voulgari C, Tentolouris N, Papadagiannis D. Increased left ventricular arrhytmogenicity in metabolic syndrome and relationship with myocardial performance, risk factors for athrerosclerosis, and low-grade inflammation. Metabolism 2010; 59: 159-165. Go to original source... Go to PubMed...
  9. N?rager B, Husic M, M?ller JE, Egstrup K. The myocardial performance index during low-dose dobutamine echocardiography in control subjects and patients with a recent myocardial infarction: a new index of left ventricular functional reserve? Journal of the American Society of echocardiography 2004; 17(7): 732-738. Go to original source... Go to PubMed...
  10. Ling LH, Tei C, McCully RB, Bailey KR, et al. Analysis of systolic and diastolic time intervals during dobutamie-atropine stress echocardiography: Diagnostic potencial of the doppler myocardial performance index. Journal of the American Society of Echocardiography 2001; 14(10): 978-986. Go to original source... Go to PubMed...
  11. Tegzova D, Ambroz D, Jansa P, et al. Possibilities of early detection of severe cardiovascular manifestation of SLE. Čes Revmatol 2007; 15(3): 131-141.
  12. Murashima S, Takeda K, Matsumura K, et al. Increased lung uptake of Iodine-123-MIBG in diabetics with sympathetic nervous dysfunction. J Nucl Med 1998; 39(2): 334-338. Go to PubMed...
  13. Scott A, Kench PL. Cardiac autonomic neuropathy in diabetic patient: does 123I-MIBG imaging have role to play in early diagnosis? J Nucl Med Technol 2004; 32: 66-71.
  14. Bakala J, Bernatek J, Kurfürst P, Adamikova A. Srovnání adrenergní inervace srdeční u pacientů s diabetes mellitus a normálních pacientů pomocí 123IMIBG metodou planární scintigrafie a metodou SPECT. [abstract] Čas Lék Čes 2011; 150(2): 116-117.
  15. Agostini D, Verberne HJ, Hamon M, et al. Cardiac 123I-MIBG scintigraphy in heart failure. J Nucl Med Mol Imaging 2008; 52(4): 369-377. Go to original source...
  16. Agostini D, Carrrio I, Verberne HJ. How to use myocardial 123 I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 2009; 36: 555-559. Go to original source... Go to PubMed...
  17. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: designe of two prospective multicenter international trials. J Nucl Card 2009; 16(1): 113-121. Go to original source... Go to PubMed...
  18. Hughes S. ACC: ADMIRE-HF: new imaging test helps better define risk in heart failure. 2009; http://www.medscape.com/viewarticle/590516.
  19. Adamikova A, Bakala J, Bernatek J, et al. Transient ischemic dilation ratio (TID) correlates with HbA1c in patients with diabetes type 2 with proven myocardial ischemia according to exercise myocardial SPECT. Ann Nucl Med 2006; 20(9): 615-621. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.